Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Non-Small Cell Lung Cancer NSCLC 1

Interventions

Cisplatin 725Carboplatin 607Paclitaxel 578Cyclophosphamide 516Radiotherapy 511Docetaxel 475Fluorouracil 453Gemcitabine 437Doxorubicin 383Capecitabine 361Dexamethasone 327Oxaliplatin 288pembrolizumab 283Leucovorin 282Bevacizumab 275Etoposide 271Vincristine 270Rituximab 246Prednisone 222Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 175Irinotecan 172Methotrexate 171Lenalidomide 137Nivolumab 135Filgrastim 135Epirubicin 129Tamoxifen 127

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × alfatide II × Clear all
NCT06416852 2024-05-16

Clinical Study of 18F-Alfatide Injection PET/CT

Yantai LNC Biotechnology Singapore PTE. LTD.

Phase 3 Not yet recruiting
428 enrolled
Thoracic

Non-Small Cell Lung Cancer NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡